Dow Jones
38.064,13 +160,84 (+0,42%) Nasdaq
15.733,95 +128,47 (+0,82%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0724 +0,0006 (+0,05%) Bitcoin EUR
55.091,63 +2.026,52 (+3,82%) CMC Crypto 200
1.273,22 +2,47 (+0,19%)
Olink Holding AB (publ) (OLK)
| Chiusura precedente | 22,68 |
| Aperto | 22,75 |
| Denaro | 22,92 x 100 |
| Lettera | 22,98 x 100 |
| Min-Max giorno | 22,51 - 23,05 |
| Intervallo di 52 settimane | 14,10 - 26,01 |
| Volume | |
| Media Volume | 550.632 |
| Capitalizzazione | 2,857B |
| Beta (5 anni mensile) | 0,50 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,25 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireLandmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics
UPPSALA, Sweden, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of three articles in the prestigious scientific journal, Nature, that demonstrate the power of the Olink Explore platform for driving impactful proteogenomic studies at the population scale. The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Bioba
- GlobeNewswire
Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
Discover more with less. Unmatched specificity and sensitivity deliver translational insights from 1µl of sample.Uppsala, Sweden, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research. Discover more with less. Unmatched specificity and sensitivity deliver translational insights from 1µl of sample. UPPSALA, Sweden, September 19, 2023 (GLOBE NEWSWIRE) – Olink Holding AB (publ) (Nas
- GlobeNewswire
Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs
Uppsala, Sweden, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs UPPSALA, Sweden, 12th September, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields of research, population health, and regulated clinical trials through the application of Olink technology. The Olink platform rep
